Esophageal and Gastric Registry and Biorepository

Gastro Esophageal Reflux Clinical Trial

Official title:

Healthy Control Esophageal and Gastric Registry and Biorepository

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05180253
• Other study ID #: 20.0990
• Status: Recruiting
• Start date: January 9, 2023
• Est. completion date: November 2025

Study information

• Verified date: April 2024
• Source: University of Louisville
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The evaluation of the foregut, the esophagus and stomach, has come a long way over the past two decades, and continues to experience exciting discoveries in the clinical evaluation of foregut physiology. Assessing esophageal peristalsis has relied for the past several decades on High Resolution Manometry (HRM), however it has recently become known that even though HRM is an extremely effective tool, that there are certain subsets of patients in which additional information is required. Additionally, the assessment of esophageal reflux disease has relied on pH impedance for the last two decades. However, this procedure requires a catheter to be passed through a nostril and remain in place for at least 24 hours. Novel techniques, already FDA approved, including EndoFLIP for esophageal peristalsis and mucosal integrity (MI) for reflux disease, have emerged as time-of-endoscopy assessments. Both involve the placement of a balloon through the scope at time of upper endoscopy (standard first line assessment for both dysphagia and reflux symptoms) and are quick and pose little-to-no additional risk or discomfort for patients. However, data regarding normal esophageal parameters are poorly defined for both EndoFLIP and MI. Additionally, EndoFLIP has increasingly been used to assess the pylorus, and scarce data exists there regarding how a tool originally envisioned for esophageal assessment can be used more distally in the GI tract. We will recruit healthy, asymptomatic volunteers to undergo testing with MI and FLIP (esophageal and pyloric). The data obtained will help establish the benchmark from which assessments can be made in patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: November 2025
• Est. primary completion date: November 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Age 18-85
• No prior surgical history
• Asymptomatic according to gastroesophageal and gastric questionnaires
• Not currently taking any medications that affect acid secretion or gut motility
• No history of malignancy
• No mental health issues precluding informed consent
• No smoking history
• No excessive or daily alcohol use
• BMI < 30
• No known hiatus hernia
• No known medical illness (autoimmune, neurological) that could be associated with altered esophageal or gastric function
• Not allergic to fentanyl or versed
• No history of eating disorder
• No history of autoimmune disorders

Exclusion Criteria:

• Minors
• Surgeries involving the GI tract
• Medication use affecting acid secretion or gut motility
• Personal history of malignancy
• Mental health issues precluding informed consent
• Symptoms on standard clinical questionnaires
• Pregnant - the effect that pregnancy has on esophageal and gastric motility is not well defined, but we will need to eliminate this as a confounding factor
• Nursing women - although the investigations are FDA approved and part of standard clinic practices, they are time consuming and involve medication administration that might affect the ability of a mother to nurse

Related Conditions & MeSH terms

• Gastro Esophageal Reflux
• Gastroesophageal Reflux

Intervention

Diagnostic Test:
• Esophageal studies
Healthy subjects will undergo esophageal and blood testing.

Locations

Country	Name	City	State
United States	Norton Healthcare	Louisville	Kentucky

Sponsors (1)

Lead Sponsor	Collaborator
University of Louisville

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Normative mucosal integrity values	We will establish the range of MI values in healthy, asymptomatic individuals.	1 year
Primary	Normative pyloric FLIP values	We will further establish the range of FLIP values that can be seen in healthy, asymptomatic individuals.	1 year